168 related articles for article (PubMed ID: 17360129)
1. The matrix metalloproteinases as pharmacological target in osteoarthritis: statins may be of therapeutic benefit.
Wu YS; Hu YY; Yang RF; Wang Z; Wei YY
Med Hypotheses; 2007; 69(3):557-9. PubMed ID: 17360129
[TBL] [Abstract][Full Text] [Related]
2. Comment on "the matrix metalloproteinases as pharmacological target in osteoarthritis: statins may be of therapeutic benefit".
Liu YP; Yu GR
Med Hypotheses; 2010 Feb; 74(2):394-5. PubMed ID: 19846258
[No Abstract] [Full Text] [Related]
3. The role of cytokines in osteoarthritis pathophysiology.
Fernandes JC; Martel-Pelletier J; Pelletier JP
Biorheology; 2002; 39(1-2):237-46. PubMed ID: 12082286
[TBL] [Abstract][Full Text] [Related]
4. An inflammation-responsive transcription factor in the pathophysiology of osteoarthritis.
Ray A; Ray BK
Biorheology; 2008; 45(3-4):399-409. PubMed ID: 18836240
[TBL] [Abstract][Full Text] [Related]
5. Effect of inhibition of matrix metalloproteinases on cartilage loss in vitro and in a guinea pig model of osteoarthritis.
Sabatini M; Lesur C; Thomas M; Chomel A; Anract P; de Nanteuil G; Pastoureau P
Arthritis Rheum; 2005 Jan; 52(1):171-80. PubMed ID: 15641085
[TBL] [Abstract][Full Text] [Related]
6. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.
Baragi VM; Becher G; Bendele AM; Biesinger R; Bluhm H; Boer J; Deng H; Dodd R; Essers M; Feuerstein T; Gallagher BM; Gege C; Hochgürtel M; Hofmann M; Jaworski A; Jin L; Kiely A; Korniski B; Kroth H; Nix D; Nolte B; Piecha D; Powers TS; Richter F; Schneider M; Steeneck C; Sucholeiki I; Taveras A; Timmermann A; Van Veldhuizen J; Weik J; Wu X; Xia B
Arthritis Rheum; 2009 Jul; 60(7):2008-18. PubMed ID: 19565489
[TBL] [Abstract][Full Text] [Related]
7. [Progress of research in osteoarthritis. The anti-inflammatory effects of intra-articular injected statin on experimental osteoarthritis].
Akasaki Y; Matsuda S; Iwamoto Y
Clin Calcium; 2009 Nov; 19(11):1653-62. PubMed ID: 19880999
[TBL] [Abstract][Full Text] [Related]
8. Production of matrix metalloproteinases and their inhibitors in osteoarthritic patients undergoing mud bath therapy.
Bellometti S; Richelmi P; Tassoni T; Bertè F
Int J Clin Pharmacol Res; 2005; 25(2):77-94. PubMed ID: 16060398
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids of patients with temporomandibular joint osteoarthritis.
Kanyama M; Kuboki T; Kojima S; Fujisawa T; Hattori T; Takigawa M; Yamashita A
J Orofac Pain; 2000; 14(1):20-30. PubMed ID: 11203734
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of cartilage destruction in osteoarthritis.
Ishiguro N; Kojima T; Poole AR
Nagoya J Med Sci; 2002 Nov; 65(3-4):73-84. PubMed ID: 12580533
[TBL] [Abstract][Full Text] [Related]
11. Update on the biology of the chondrocyte and new approaches to treating cartilage diseases.
Goldring MB
Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):1003-25. PubMed ID: 16980220
[TBL] [Abstract][Full Text] [Related]
12. Esculetin (dihydroxycoumarin) inhibits the production of matrix metalloproteinases in cartilage explants, and oral administration of its prodrug, CPA-926, suppresses cartilage destruction in rabbit experimental osteoarthritis.
Yamada H; Watanabe K; Saito T; Hayashi H; Niitani Y; Kikuchi T; Ito A; Fujikawa K; Lohmander LS
J Rheumatol; 1999 Mar; 26(3):654-62. PubMed ID: 10090178
[TBL] [Abstract][Full Text] [Related]
13. Can statins suppress the development of abdominal aortic aneurysms? A review of the current evidence.
Saratzis A; Kitas GD; Saratzis N; Melas N
Angiology; 2010 Feb; 61(2):137-44. PubMed ID: 19625274
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes.
Tetlow LC; Adlam DJ; Woolley DE
Arthritis Rheum; 2001 Mar; 44(3):585-94. PubMed ID: 11263773
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability.
Johnson JL
Expert Rev Cardiovasc Ther; 2007 Mar; 5(2):265-82. PubMed ID: 17338671
[TBL] [Abstract][Full Text] [Related]
16. [Progress of research in osteoarthritis. Metalloproteinases in osteoarthritis].
Okada A; Okada Y
Clin Calcium; 2009 Nov; 19(11):1593-601. PubMed ID: 19880991
[TBL] [Abstract][Full Text] [Related]
17. Metalloproteases and inhibitors in arthritic diseases.
Martel-Pelletier J; Welsch DJ; Pelletier JP
Best Pract Res Clin Rheumatol; 2001 Dec; 15(5):805-29. PubMed ID: 11812023
[TBL] [Abstract][Full Text] [Related]
18. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages.
Luan Z; Chase AJ; Newby AC
Arterioscler Thromb Vasc Biol; 2003 May; 23(5):769-75. PubMed ID: 12663370
[TBL] [Abstract][Full Text] [Related]
19. [Progress of research in osteoarthritis. An overview of the recent knowledge on osteoarthritis: pathogenesis, evaluation and therapies].
Kimura T
Clin Calcium; 2009 Nov; 19(11):1565-71. PubMed ID: 19880987
[TBL] [Abstract][Full Text] [Related]
20. Effect of nimesulide on metalloproteinases and matrix degradation in osteoarthritis: a pilot clinical study.
Kullich WC; Niksic F; Klein G
Int J Clin Pract Suppl; 2002 Jul; (128):24-9. PubMed ID: 12166616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
